MedTrace Logo

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

NCT00306787 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1179

Last updated 2011-06-30

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).

Conditions

  • Genital Herpes

Interventions

DRUG

Famciclovir

Famciclovir 500 mg tablet

DRUG

Valacyclovir

Valacyclovir 500 mg capsule

DRUG

Placebo matching famciclovir

Famciclovir placebo, matching in size, color and forms of famciclovir tablet.

DRUG

Placebo matching valacyclovir

Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States
  • Australia
  • Canada
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00306787 on ClinicalTrials.gov